Cancer and Stem Cell Biology Laboratory, Department of Genetic Engineering, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, TamilNadu 603203, India.
ACS Appl Bio Mater. 2024 Nov 18;7(11):7076-7087. doi: 10.1021/acsabm.4c00660. Epub 2024 Nov 4.
Extracellular vesicles (EVs) are cellular communication molecules and are classified into three major subpopulations, such as microvesicles, apoptotic bodies, and exosomes. Among these, exosomes-based cancer research is a cutting-edge investigation approach to cancer understanding. During cancer progression , tumor-derived exosomes can reprogram the cellular system and promote cancer. Circulating exosomes in the body fluids such as blood, plasma, serum, saliva, CSF, sweat, and tears play a key role in identifying diagnostic and prognostic cancer biomarkers. Diverse therapeutic sources of exosomes including stem cells, plants, and immune cells, etc. exhibit significant cancer-healing properties. Although cancer-targeting immunotherapy is an effective strategy, it has limitations such as toxicity, and high costs. In comparison, immune cell-derived exosomes-based immunotherapy is a cell-free approach for cancer treatment and has advantages like less toxicity, biocompatibility, reduced immunogenicity, and efficient, target-specific cancer therapeutic development. This review highlights the therapeutic signature of immune cell-derived exosomes for cancer treatment.
细胞外囊泡 (EVs) 是细胞通讯分子，可分为三大亚群，如微囊泡、凋亡小体和外泌体。其中，基于外泌体的癌症研究是一种癌症研究的前沿方法。在癌症进展过程中，肿瘤来源的外泌体可以重新编程细胞系统并促进癌症。体液中的循环外泌体，如血液、血浆、血清、唾液、CSF、汗液和眼泪，在识别诊断和预后癌症生物标志物方面发挥着关键作用。包括干细胞、植物和免疫细胞在内的多种外泌体治疗来源具有显著的癌症治疗特性。虽然癌症靶向免疫疗法是一种有效的策略，但它存在毒性和高成本等局限性。相比之下，免疫细胞来源的外泌体免疫疗法是一种用于癌症治疗的无细胞方法，具有毒性低、生物相容性好、免疫原性降低以及高效、特异性靶向癌症治疗开发等优点。本综述强调了免疫细胞来源的外泌体在癌症治疗中的治疗特征。
